# A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

> **NCT03496571** · PHASE2 · COMPLETED · sponsor: **Allakos Inc.** · enrollment: 65 (actual)

## Conditions studied

- Eosinophilic Gastritis
- Eosinophilic Gastroenteritis

## Interventions

- **DRUG:** AK002
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03496571
- **Lead sponsor:** Allakos Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-18
- **Primary completion:** 2019-06-24
- **Final completion:** 2019-06-24
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03496571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03496571, "A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03496571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*